To the Editor: The systematic review by Dr Annane and colleagues1 summarized the results of 22 clinical trials investigating corticosteroid therapy in sepsis. The review suggested that prolonged low-dose corticosteroid therapy (≥5 days, ≤300 mg/d of hydrocortisone or equivalent) decreases mortality and recommended treating adult patients with vasopressor-dependent septic shock. However, we believe that these recommendations are weakened by possible publication bias and by the relationship between severity of illness and the treatment effect of corticosteroids.
The review stated that “the funnel plot did not suggest evidence for publication bias.”1 However, in a recent systematic review of corticosteroids in sepsis,2 we demonstrated publication bias within the group of trials investigating prolonged low-dose corticosteroids using an Egger regression test3 and a funnel plot. Therefore, we recommend performing similar analyses to examine the 12 trials investigating prolonged low-dose corticosteroids included in this review. Findings consistent with publication bias would imply that the overall reported improvement in mortality may be due to inclusion of a disproportionately high number of small trials demonstrating beneficial effects of corticosteroids. Small negative trials may be unavailable for inclusion because they were either not reported or not accepted for publication. Potential publication bias is concerning because the CORTICUS trial, accounting for more than 40% of patients in this subgroup analysis, demonstrated no benefit of low-dose corticosteroids in patients with vasopressor-dependent septic shock.4
The review also suggested an interaction between mortality in the control group and the effects of corticosteroid therapy (P = .06).1 We recommend examining the data (excluding the Schumer trial for consistency with the other analyses) for a relationship between severity of illness (measured by control group mortality) and treatment effect, using fixed-effects or unrestricted maximum likelihood models. If significant, this would suggest that low-dose corticosteroids decrease mortality only in more severely ill patient populations and would be consistent with our findings2 and with reported effects of other anti-inflammatory agents in sepsis.5 Furthermore, such a relationship might in part explain the lack of benefit in the CORTICUS trial, which had a relatively low control mortality (31%) compared with the other the trials (median [interquartile range], 44% [25%-61%]).1 ,4
Long-course low-dose corticosteroids may improve survival only in severely ill patients with refractory vasopressor-dependent septic shock. Until further data become available, we believe that decisions to treat severely ill septic patients with corticosteroids should be based on individual patient risk-benefit assessments.
Financial Disclosures: None reported.
Country-Specific Mortality and Growth Failure in Infancy and Yound Children and Association With Material Stature
Use interactive graphics and maps to view and sort country-specific infant and early dhildhood mortality and growth failure data and their association with maternal
Instructions
Comments are moderated and will appear on the site at the discretion of the Journal of American Medical Association editors. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest* Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more
Subscribe for full-text access to content from 1998 forward and a host of useful features
Activate your current subscription (AMA members and current subscribers)
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Customize your page view by dragging & repositioning the boxes below.
and access these and other features:
Register Now
Enter your username and email address. We'll send you a reminder to the email address on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.